| Phase 3 |
| NCT05862285 |
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La… |
Cancer |
Recruiting |
| NCT04650581 |
Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive… |
Breast Cancer |
Active, Not Recruiting |
| Phase 2 |
| NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced… |
Advanced Malignant Solid Neoplasm |
Recruiting |
| NCT04920708 |
Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer… |
Metastatic Breast Cancer |
Active, Not Recruiting |
| NCT04589845 |
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You… |
Solid Tumors |
Active, Not Recruiting |
| NCT05498896 |
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab… |
Triple Negative Breast Cancer |
Active, Not Recruiting |
| NCT05172258 |
Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy… |
Head and Neck Squamous Cell Carcinoma |
Active, Not Recruiting |
| NCT06400251 |
Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes… |
Advanced Lymphoma |
Active, Not Recruiting |
| NCT02465060 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced… |
Advanced Lymphoma |
Active, Not Recruiting |
| NCT04931342 |
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With… |
Ovarian Cancer |
Active, Not Recruiting |
| Phase 1/2 |
| NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients… |
Metastatic Breast Cancer |
Recruiting |
| NCT04486352 |
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer |
Endometrial Cancer |
Recruiting |
| NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in… |
Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer |
Recruiting |
| NCT05538897 |
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal… |
FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma |
Active, Not Recruiting |
| Phase 1 |
| NCT05172245 |
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck… |
Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 |
Recruiting |